Two prominent examples of the clinically significant HERV/LTR activation have been reported: CSF1R oncogene activation by a MaLR LTR in Hodgkin’s lymphoma and RCC-specific novel HERV-E antigen expression facilitating the immunotherapy. This evidence concerns the gene CSF1R and renal cell carcinoma.